Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN). The abstract was presented at the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. during the Late-Breaking News session on November 15, 2016.
The late-breaking abstract, titled, “Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study,” was presented by Mary Anne Dooley, M.D., M.P.H., of the University of North Carolina Kidney Center. The global Phase IIb AURA study of voclosporin, a novel immunosuppressant that has been applied as a treatment for LN, is the first global active lupus nephritis study to meet its primary endpoint. In addition, all secondary endpoints in AURA were met, including demonstrating a more rapid response rate for patients receiving voclosporin versus patients in the control arm with most patients achieving complete remission (CR) at or before the eighth week of the trial.
“Lupus nephritis is a devastating, often overlooked disease that severely impacts a patient’s quality of life and, in the worst cases, can lead to end-stage renal disease or even death,” said Dr. Dooley. “The ability to get more patients into remission and in a shorter period of time than the current standard of care can have a significant impact on the long-term outcomes for these patients. We have demonstrated that voclosporin successfully achieves not only higher complete remission rates but does so more rapidly in patients with LN. I believe this promising data has the potential to shift the standard of care and improve long-term outcomes for patients with LN.” (Original Source)
Shares of Aurinia Pharmaceuticals are up 13% to $4.38 in Wednesday’s trading session. AUPH has a 1-year high of $5.69 and a 1-year low of $1.42. The stock’s 50-day moving average is $3.86 and its 200-day moving average is $2.84.
On the ratings front, Aurinia has been the subject of a number of recent research reports. In a report issued on November 7, H.C. Wainwright analyst Ed Arce reiterated a Buy rating on AUPH. Separately, on November 3, FBR’s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $9.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ed Arce and Vernon Bernardino have a yearly average return of 16.9% and a loss of 18.0% respectively. Arce has a success rate of 35% and is ranked #232 out of 4223 analysts, while Bernardino has a success rate of 26% and is ranked #4119.
Sentiment on the Street is mostly bullish on AUPH stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating .
Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovery and development of immunomodulating therapeutics. Its products include voclosporin and non-immunosuppressive cyclosporine analogue molecules for the treatment of lupus nephritis.